BMS Grows Its Lung Cancer Portfolio With ‘Best-In-Class’ Augtyro Approval
Drug Addresses 1%-2% Of NSCLC Patients
Bristol Myers Squibb won US FDA approval for Augtyro (repotrectinib), from its $4.1bn Turning Point acquisition last year, in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
